請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63571
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李心予 | |
dc.contributor.author | SHUN-YAN LAN | en |
dc.contributor.author | 藍順彥 | zh_TW |
dc.date.accessioned | 2021-06-16T17:14:10Z | - |
dc.date.available | 2013-08-24 | |
dc.date.copyright | 2012-08-20 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-20 | |
dc.identifier.citation | [1] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007 CA Cancer J Clin. 2007; 57: 43-66.
[2] Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000; 14: 2410-2434. [3] DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003; 361: 955-964. [4] Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45. [5] Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst. 2001; 93: 1687-1697. [6] Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-593. [7] Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg Oncol. 2006; 15: 117-128. [8] Song J, Clagett-Dame M, Peterson RE, Hahn ME, Westler WM, Sicinski RR, DeLuca HF. A ligand for the aryl hydrocarbon receptor isolated from lung. Proc Natl Acad Sci USA. 2002; 99: 14694-14699. [9] Henry EC, Bemis JC, Henry O, Kende AS, Gasiewicz TA. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch Biochem Biophys. 2006; 450: 67-77. [10] Sommer RJ, Sojka KM, Pollenz RS, Cooke PS, Peterson RE. Ah receptor and ARNT protein and mRNA concentrations in rat prostate: effects of stage of development and 2,3,7, 8-tetrachlorodibenzo-p-dioxin treatment. Toxicol Appl Pharmacol. 1999; 155: 177-189. [11] Kashani M, Steiner G, Haitel A, Schaufler K, Thalhammer T, Amann G, Kramer G, Marberger M, Schöller A. Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate. Prostate. 1998; 37: 98–108. [12] Fritz WA, Lin TM, Peterson RE. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis. 2008; 29: 1077-1082. [13] Fritz WA, Lin TM, Cardiff RD, Peterson RE. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis. 2007; 28: 497-505. [14] Rodríguez-Jiménez FJ, Moreno-Manzano V. Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective. Cell Mol Life Sci. 2012 ; 69: 519-534. [15] Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol. 2009; 70: 93-102. [16] Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001; 49: 507-521. [17] Ichihara E, Kiura K, Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med Okayama. 2011; 65: 353-362. [18] Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Over-expression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59: 5830-5835. [19] Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK, Han JW, Lee HY. Activation of Hypoxia-Inducible Factor-1α Is Necessary for Lysophosphatidic Acid–Induced Vascular Endothelial Growth Factor Expression. Clin Cancer Res. 2006; 12: 6351-6358 [20] Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000; 275: 25733-25741. [21] Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim Av, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468-472. [22] Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003; 3: 582-591. [23] Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995; 1: 1223-1232. [24] Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993; 291: 677-680. [25] Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol. 1998; 9: 437-442. [26] Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002; 1582: 257-264. [27] Xie Y, Gibbs TC, Mukhin YV, Meier KE. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem. 2002; 277: 32516-32526. [28] Guo C, Luttrell LM, Price DT. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol. 2000; 163: 1027-1032. [29] Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011; 2: 1097-1105. [30] Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994; 144: 1188-1194. [31] Bigler SA, Deering RE, Brawer MK. Comparison of micromicroscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993; 24: 220-226 [32] S. Kato, H. Shimoda, R.-C. Ji, M. Miura, Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers. Anat Sci Int. 2006; 8: 71-83. [33] R.C. Ji. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: new insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev. 2006; 25: 677-694.. [34] Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15: 290-298. [35] Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC, Kuo ML. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel-mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 2004; 64: 554-564. [36] Zeng Y, Opeskin K, Horvath LG, Sutherland RL, Williams ED. Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate. 2005; 65: 222-230. [37] Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA1/3, COX-2, and NF-κB activation- and EGFR transactivation-dependent mechanisms. Cell Signal. 2008; 20: 1804-1814 [38] Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci. 2008; 65: 2740-2751. [39] Lin C-E, Chen S-U, Lin C-C, Chang C-H, Lin Y-C, et al. Lysophosphatidic Acid Enhances Vascular Endothelial Growth Factor-C Expression in Human Prostate Cancer PC-3 Cells. PLoS ONE. 2012; 7: e41096. [40] Gupta A, Schecter A, Aragaki CC, Roehrborn CG. Dioxin exposure and benign prostatic hyperplasia. J Occup Environ Med. 2006; 48: 708–714. [41] Hsu EL, Yoon D, Choi HH, Wang F, Taylor RT, Chen N, Zhang R, Hankinson O. A proposed mechanism for the protective effect of dioxin against breast cancer. Toxicol Sci. 2007; 98: 436-444. [42] Safe S, Qin C, McDougal A. Development of selective aryl hydrocarbon receptor modulators for treatment of breast cancer. Expert Opin Investig Drugs 1999; 8: 1385–1396. [43] Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia. 2000 ; 5: 295-306. [44] Nilsson I, Shibuya M, Wennström S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res. 2004; 299: 476-485. [45] Fujii T, Otsuki T, Moriya T, Sakaguchi H, Kurebayashi J, Yata K, Uno M, Kobayashi T, Kimura T, Jo Y, Kinugawa K, Furukawa Y, Morioka M, Ueki A, Tanaka H. Effect of hypoxia on human seminoma cells. Int J Oncol. 2002; 20: 955-962. [46] Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012; 31: 2448-2460. [47] Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002; 277: 38205-38211. [48] Segrelles C, Ruiz S, Santos M, Martínez-Palacio J, Lara MF, Paramio JM. Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis. 2004; 25: 1137-1147. [49] Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl). 2012; 90: 45-54. [50] Park KY, Jeong SJ, Lee HJ, Kim SH, Lim S, Kim HC, Lü J, Kim SH. 1,2,3,4,6-Penta-O-galloly-beta-D-glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1α and signaling in LNCaP prostate cancer cells. Biol Pharm Bull. 2010; 33: 1835-1840. [51] Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Sonawane V, Rathos MJ, Kumar S, Joshi KS. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer. 2011; 11: 338. [52] Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001; 12: 363-369. [53] Wang T, Wyrick KL, Meadows GG, Wills TB, Vorderstrasse BA. Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicol Sci. 2011; 124: 291-298. [54] Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol Chem. 2006; 387: 1209-1213. [55] Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE. The Selective Aryl Hydrocarbon Receptor Modulator 6-Methyl-1,3,8-Trichlorodibenzofuran Inhibits Prostate Tumor Metastasis in TRAMP Mice. Biochem Pharmacol. 2009; 77: 1151-1160. [56] Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478: 197-203. [57] Nguyen LP, Bradfield CA. The Search for Endogenous Activators of the Aryl Hydrocarbon Receptor. Chem Res Toxicol. 2008;21:102-16. [58] Jensen KA, Luu TC, Chan WK. A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: a viable approach for breast cancer treatment. Mol Pharm. 2006; 3: 695–703. [59] Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2008; 28: 1659-1666. [60] Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999; 15: 551-578. [61] Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-732. [62] Semenza GL. Oxygen-regulated transcription factors and their role in pulmonary disease. Respir Res. 2000; 1: 159-162 [63] Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006; 70: 1469-1480. [64] Sandau KB, Fandrey J, Brüne B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood. 2001; 97: 1009-1015. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63571 | - |
dc.description.abstract | 水解磷酸脂(LPA)存在正常人體血清中而在癌症病患中濃度大增。其在癌症發生過程中,會誘發血管內皮生長因子(VEGF-A 及VEGF-C)表現。在LPA誘導VEGF-A表達的訊息路徑中,1α-缺氧誘發因子(HIF-1α)與芳香烴受體核轉位蛋白(ARNT)聚合形成缺氧誘發因子(HIF-1),進而誘發VEGF-A表現。然而,HIF-1α是否調控VEGF-C表現卻鮮為人知。由於ARNT也會與戴奧辛受體(AhR)聚合成複合物,因此我們假設AhR可藉由與HIF-1α競爭結合至ARNT,進而抑制LPA所誘導VEGF-A 及VEGF-C表現。於本研究中,我們調查AhR如何影響LPA誘導VEGF-A 及VEGF-C表現及闡明LPA誘導VEGF-A 及VEGF-C表現的分子機制。結果發現,在PC-3前列腺癌細胞株中,當AhR被過量表達或是被3-甲基膽蔥(3-methylcholanthrene, 3-MC)所活化皆會抑制LPA誘導VEGF-A 及VEGF-C表現。此外,磷脂酰肌醇3-激酶(PI3K)、HIF-1α以及ARNT皆參與調控LPA誘導VEGF-A 及VEGF-C表現。這些結果顯示,AhR可能藉由減弱LPA所刺激的HIF-1訊息路徑,因而抑制VEGF-A 與VEGF-C表現。本研究的重要性在於未來可能利用調節AhR,進而調控血管新生以及淋巴管新生,因此AhR具有成為前列腺癌細胞轉移治療標的之潛力。 | zh_TW |
dc.description.abstract | Lysophosphatidic acid (LPA) which exists in normal human serum and reaches higher concentration in cancer patients can induce expression of vascular endothelial growth factors (VEGF-A and VEGF-C), thereby modulating angiogenesis and lymphangiogenesis. In the pathway of LPA-induced VEGF-A expression in PC-3 prostate cancer cells, hypoxia-inducible factor-1 alpha (HIF-1α) dimerizes with aryl hydrocarbon receptor nuclear translocator (ARNT, identical to HIF-1β) to form hypoxia-inducible factor-1 (HIF-1), then regulating VEGF-A expression. However, the effects of HIF-1 signaling on LPA-induced VEGF-C expression have not been determined. ARNT also dimerizes with aryl hydrocarbon receptor (AhR). Since ARNT is a common dimerization partner of AhR and HIF-1α, we hypothesized that AhR has the potential to suppress LPA-induced VEGFs expression in PC-3 prostate cancer cells by competing with HIF-1α for ARNT. Herein, we determined the effects of AhR signaling on LPA-induced VEGFs expression and the underlying signaling pathway of LPA-induced VEGFs expression. AhR over-expression or activation of AhR by a selective AhR modulator (SAhRM) called 3-methylcholanthrene (3-MC) inhibited LPA-induced VEGFs expression in PC-3 cells. In addition, LPA-induced VEGF-A and VEGF-C expressions were both regulated by HIF-1α, ARNT and through activation of the phosphatidylinositol 3-kinase (PI3K) signaling. The results obtained from this study indicate that AhR inhibits LPA-induced VEGFs expression in PC-3 prostate cancer cells possibly by attenuating LPA-stimulated HIF-1 signaling pathway. Furthermore, these findings also suggest that AhR is likely to become a therapeutic target for prevention of prostate cancer metastasis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:14:10Z (GMT). No. of bitstreams: 1 ntu-101-R97b43032-1.pdf: 1034511 bytes, checksum: 48306c916b25683a0ffb79eed3a51b28 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 誌謝.......I
摘要.......II ABSTRACT.......III INTRODUCTION.......1 Prostate Cancer and Metastasis.......1 AhR and Prostate Cancer.......2 HIF-1 and Prostate Cancer.......2 LPA and Prostate Cancer.......3 LPA and Angiogenesis in Prostate Cancer.......4 LPA and Lymphangiogenesis in Prostate Cancer.......4 RATIONALE.......6 MATERIALS AND METHODS.......7 Cell culture.......7 Lentivirus production.......7 Preparation of high-titer lentivirus.......8 Lentiviral transduction.......8 Transient transfection studies.......8 LPA stimulation.......9 RNA Isolation and Reverse transcription–polymerase chain reaction (RT-PCR).......9 Quantitative real-time PCR.......10 Statistical analysis.......11 RESULTS.......12 LPA stimulates VEGF-A and VEGF-C expression in PC-3 prostate cancer cells.......12 AhR over-expression inhibits both LPA-induced VEGFA and VEGF-C expression in PC-3 prostate cancer cells.......12 Activation of AhR signaling by 3-methylcholanthrene (3-MC) inhibits both LPA-induced VEGF-A and VEGF-C expression.......13 HIF-1α is required in LPA-induced VEGF-A and VEGF-C expression.......13 ARNT (HIF-1β) is required in both LPA-induced VEGF-A and VEGF-C expression.......14 Phosphatidylinositol 3-kinase (PI3K) signaling is involved in HIF-1α expression and LPA-induced VEGF-A and VEGF-C expression.......15 DISCUSSION.......17 REFERENCE....... 21 FIGURES.......31 | |
dc.language.iso | en | |
dc.title | 戴奧辛受器在前列腺癌細胞中對於水解磷酸脂誘導的血管內皮生長因子訊息傳遞路徑影響之研究 | zh_TW |
dc.title | Effects of Aryl Hydrocarbon Receptor on LPA-induced Vascular Endothelial Growth Factors Expression in Human PC3 Prostate Cancer Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳俊宏,黃元勵 | |
dc.subject.keyword | 水解磷酸脂,血管內皮生長因子,缺氧誘發因子,戴奧辛受體,血管新生,淋巴管新生,芳香烴受體核轉位蛋白, | zh_TW |
dc.subject.keyword | LPA,VEGF-A,VEGF-C,HIF-1,AhR,angiogenesis,lymphangiogenesis,ARNT, | en |
dc.relation.page | 46 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-20 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 動物學研究所 | zh_TW |
顯示於系所單位: | 動物學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.01 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。